Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E.
Zorde Khvalevsky E, et al. Among authors: shemi a.
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20723-8. doi: 10.1073/pnas.1314307110. Epub 2013 Dec 2.
Proc Natl Acad Sci U S A. 2013.
PMID: 24297898
Free PMC article.